Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ativan Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

NCT03090620
View directory record Official record
Conditions
Anticholinergics Toxicity
Interventions
Physostigmine, Lorazepam
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ADASUVE-Lorazepam Drug-Drug Interaction

NCT01877642
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 7, 2026, 1:53 AM EDT
Terminated Phase 3 Interventional Results available

Stanford Accelerated Recovery Trial (START)

NCT01067144
View directory record Official record
Conditions
Pain, Breast Cancer, Lung Cancer
Interventions
Gabapentin, Lorazepam (active control), Placebo (inactive)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

Dextromethorphan to Treat Patients With Voice Spasms

NCT00055549
View directory record Official record
Conditions
Voice Disorders
Interventions
Dextromethorphan, Lorazepam
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 1:53 AM EDT
Completed No phase listed Observational

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)

NCT01810458
View directory record Official record
Conditions
Liver Fibrosis, Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD
Interventions
Abdominal ultrasound, History and physical, Intravenous catheter, Blood draw, Liver questionnaire, Liver Biopsy, Midazolam, Fentanyl, Lidocaine, Acetaminophen, Lorazepam, Oxycodone/Acetaminophen, Ondansetron
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

NCT00513565
View directory record Official record
Conditions
Depressive Disorder and Anxiety Disorders
Interventions
single dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Results available

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

NCT00457366
View directory record Official record
Conditions
Agitation
Interventions
Quetiapine, Haloperidol, Lorazepam, Cogentin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam

NCT00229125
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome(AWS)
Interventions
Gabapentin, Lorazepam
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2005 · Synced Sep 7, 2026, 1:53 AM EDT
Completed No phase listed Observational

Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

NCT03071913
View directory record Official record
Conditions
Central Nervous System Neoplasm, Localized Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Not applicable Interventional

A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal

NCT00523185
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Lorazepam, Diazepam
Drug
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2007 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Results available

A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise

NCT02407704
View directory record Official record
Conditions
Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions
Venlafaxine XR, Aerobic Exercise, Lorazepam
Drug · Other
Lead sponsor
Kirk Erickson, PhD
Other
Eligibility
60 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 2Phase 3 Interventional

Lorazepam Sedation for Critically Ill Children

NCT00109395
View directory record Official record
Conditions
Critical Illness
Interventions
Lorazepam, Midazolam, Lorazepam CI
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
1 Day to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 7, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 7, 2026, 1:53 AM EDT
Withdrawn Phase 1Phase 2 Interventional

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

NCT00123578
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Lorazepam, Pentobarbital
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

NCT03331042
View directory record Official record
Conditions
Transient Insomnia
Interventions
SM-1, D+Z, D+L, Placebo
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 7, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Comparing the Effectiveness of Oral Versus Intravenous Pain Medicine for Suction Curettage (D&C)

NCT00337792
View directory record Official record
Conditions
Undesired Pregnancy
Interventions
oxycodone + lorazepam versus fentanyl + midazolam
Drug
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Sep 7, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Results available

The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children

NCT00580151
View directory record Official record
Conditions
Pain, Anxiety
Interventions
clonidine, placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
4 Years to 20 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Glutamatergic Modulation of Cocaine-related Deficits

NCT01790490
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Ketamine 0.41 mg/kg, Ketamine 0.71 mg/kg, Lorazepam 2 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 52 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

NCT00807937
View directory record Official record
Conditions
Anxiety Disorders
Interventions
AZD7325, Lorazepam, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Mesa, Arizona • Little Rock, Arkansas • Carson, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Sep 7, 2026, 1:53 AM EDT
Completed No phase listed Observational

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

NCT05438641
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
BZDP-Sparing Protocol, BZDP-Based Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lorazepam-Induced Toxicity in the Aged

NCT00044642
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Lorazepam
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
60 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Sep 7, 2026, 1:53 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 7, 2026, 1:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test

NCT00972985
View directory record Official record
Conditions
Healthy
Interventions
modafinil, methylphenidate, lorazepam, placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 7, 2026, 1:53 AM EDT